What are the alternative antibiotics for anaerobic coverage excluding Zosyn (piperacillin/tazobactam)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Alternative antibiotics for anaerobic coverage besides Zosyn include metronidazole, clindamycin, carbapenems (meropenem, imipenem, ertapenem), moxifloxacin, and tigecycline. According to the guidelines for the selection of anti-infective agents for complicated intra-abdominal infections 1, and the diagnosis and management of complicated intra-abdominal infection in adults and children 1, these antibiotics are recommended for anaerobic coverage.

Key Points to Consider

  • Metronidazole (500 mg IV/PO every 8 hours) is often the first choice due to its excellent anaerobic spectrum, particularly against Bacteroides fragilis, and minimal resistance 1.
  • Clindamycin (600-900 mg IV every 8 hours) provides good coverage but has increasing resistance rates 1.
  • Carbapenems offer broad-spectrum coverage including anaerobes, with meropenem (1 g IV every 8 hours), imipenem (500 mg IV every 6 hours), or ertapenem (1 g IV daily) being effective options for serious infections 1.
  • Moxifloxacin (400 mg IV/PO daily) provides moderate anaerobic coverage along with gram-positive and gram-negative activity 1.
  • Tigecycline (100 mg IV loading dose, then 50 mg IV every 12 hours) covers anaerobes but has limitations including FDA warnings about mortality risk 1.

Patient Factors to Consider

  • Infection site and severity
  • Patient allergies and renal function
  • Local resistance patterns

Additional Considerations

  • Combination therapy may be necessary for polymicrobial infections, such as metronidazole plus a cephalosporin for broader coverage 1.

From the FDA Drug Label

Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70 kg adult) for metronidazole.

Alternative antibiotics for anaerobic coverage (excluding Zosyn) are:

  • Metronidazole 2: used to treat serious anaerobic infections
  • Clindamycin 3: indicated in the treatment of serious infections caused by susceptible anaerobic bacteria

From the Research

Alternative Antibiotics for Anaerobic Coverage

Excluding Zosyn (piperacillin/tazobactam), the following antibiotics can be used for anaerobic coverage:

  • Metronidazole, which is highly effective against all species of anaerobes except certain non-spore-forming gram-positive bacilli and cocci 4
  • Clindamycin, which has been used successfully in some anaerobic infections, although its susceptibility has decreased over time 5
  • Imipenem, which is one of the most active agents against anaerobic bacteria 5, 6
  • Meropenem, which has been shown to be highly active against anaerobic bacteria and is a promising antimicrobial agent for anaerobic infections 6, 7
  • Chloramphenicol, which is effective against anaerobic organisms 5, 7
  • Tigecycline, which is effective against anaerobic organisms 7
  • Combinations of a penicillin and a beta-lactamase inhibitor, such as ampicillin or ticarcillin plus clavulanate, amoxicillin plus sulbactam 7
  • RP 59500, a new streptogramin, which has been shown to be highly active against anaerobic bacteria 8
  • Cefoxitin, which has been used successfully in some anaerobic infections 5
  • Fluoroquinolones, which exhibit good activity against Gram-positive cocci and anaerobes 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Metronidazole.

Mayo Clinic proceedings, 1983

Research

Anti-anaerobic activity of antibacterial agents.

Expert opinion on investigational drugs, 2001

Research

Susceptibility of anaerobic bacteria to meropenem.

The Journal of antimicrobial chemotherapy, 1989

Research

Treatment of anaerobic infection.

Expert review of anti-infective therapy, 2007

Research

Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1989

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.